Codexis Announces Achievement Of Gram-Scale Synthesis With Its ECO Synthesis Platform; Milestone Enables Codexis Engineers To Model The Manufacturing Process For RNai Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Codexis, Inc. (NASDAQ:CDXS) has achieved gram-scale synthesis with its ECO Synthesis Platform, a significant step in the development of RNAi therapeutics manufacturing. This milestone allows Codexis engineers to model the manufacturing process and initiate pre-commercial customer testing in 2024, with a full commercial launch expected in 2026. The company's progress was highlighted during a virtual KOL investor event with industry experts discussing the potential of the ECO Synthesis Platform.
December 13, 2023 | 9:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Codexis has achieved a significant milestone in RNAi therapeutics with its ECO Synthesis Platform, enabling the modeling of manufacturing processes and setting the stage for pre-commercial testing in 2024 and a commercial launch in 2026.
The achievement of gram-scale synthesis is a critical technical milestone for Codexis, indicating significant progress in the development of its ECO Synthesis Platform. This advancement is likely to be viewed positively by investors as it demonstrates the company's ability to meet its development timelines and move closer to commercialization. The news may increase investor confidence in the company's technology and future revenue potential, potentially leading to a short-term positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100